Microgeste (Ethinylestradiol, Gestodene | Lactose Monohydrate)

The ethinylestradiol component supplies estrogen activity, while gestodene provides progestogenic activity. Together they suppress the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, preventing ovulation, and they also thicken cervical mucus and alter the endometrium to reduce the chance of implantation.

The dosing regimen for Microgeste is determined by the prescribing clinician. Typically, a single tablet is taken once daily at the same time each day, but the exact schedule and duration are individualized based on patient needs and medical guidance.

Microgeste is not indicated for use during pregnancy and should be discontinued if pregnancy occurs. Limited data are available for breastfeeding; because estrogen may affect milk production, clinicians usually advise caution and consider alternative contraception for nursing mothers.

To request Microgeste, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgeste contains ethinylestradiol and gestodene, a low‑dose estrogen‑progestin combination that offers a favorable bleeding profile and high contraceptive efficacy. Compared with older formulations that use higher estrogen doses, Microgeste may present a lower risk of estrogen‑related side effects while maintaining comparable pregnancy‑prevention rates.

Store Microgeste tablets at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, excessive heat and direct sunlight. Keep the container tightly closed and out of reach of children.

Microgeste is taken orally with a glass of water, preferably at the same time each day. The tablet should be swallowed whole and not chewed or broken. Consistent daily intake maximizes contraceptive effectiveness.

Serious risks include venous thromboembolism such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe allergic reactions and liver tumors have also been reported. Patients should seek immediate medical attention if they experience symptoms like sudden leg pain, shortness of breath, chest pain, severe headache, or unexplained swelling.

Microgeste is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals with known hypersensitivity to any component of the tablet.